{"transactions":[{"id":4628427,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":28933,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":482478,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":28933},"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628426,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2600,"price":93.46,"value":242996.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2845,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628425,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":92.7,"value":194670.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":5445,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628424,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":7228,"price":91.35,"value":660277.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":7545,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628423,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":16605,"price":90.35,"value":1500261.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":14773,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628422,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":89.24,"value":35696.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":31378,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628421,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-10-03T01:30:15.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":28933,"price":14.5,"value":419528.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."}],"balance_after":31778,"source":{"system":"sec-edgar","filing":"0001636282-26-000119","document":"wk-form4_1790991012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000119/wk-form4_1790991012.xml","form_type":"4"}},{"id":4628437,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":93.91,"value":9391.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":537540,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628436,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":4990,"price":93.37,"value":465916.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":537640,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628435,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3989,"price":92.31,"value":368224.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.87 to $92.86, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":542630,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628434,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2638,"price":91.49,"value":241350.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.85 to $91.84, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":546619,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628433,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2683,"price":90.1,"value":241738.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.80 to $90.76, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":549257,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628432,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":89.14,"value":53484.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":551940,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628448,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":312357,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628447,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T01:29:27.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":319857,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628446,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":229,"price":93.57,"value":21427.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":79762,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628445,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3071,"price":92.95,"value":285449.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":79991,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628444,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":91.92,"value":193032.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":83062,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628443,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":90.27,"value":135405.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":85162,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628442,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":89.07,"value":53442.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":86662,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628441,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":87262,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628440,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":17500,"price":89.89,"value":1573075.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":79762,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4628439,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:27.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":17500,"price":14.5,"value":253750.0,"ownership":{"direct":true},"balance_after":97262,"source":{"system":"sec-edgar","filing":"0001636282-26-000117","document":"wk-form4_1790990964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000117/wk-form4_1790990964.xml","form_type":"4"}},{"id":4046,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":511411,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4045,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":27999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":511811,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":27999},"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4044,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":400,"price":90,"value":36000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":2845,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4043,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":14.5,"value":5800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":3245,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4042,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":89.38,"value":35752.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":2845,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4041,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":6206,"price":88.17,"value":547183.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.73 to $88.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":3245,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4040,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":16548,"price":87.2,"value":1442985.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.71 to $87.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":9451,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4039,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":4845,"price":86.4,"value":418608.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.71 to $86.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":25999,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4038,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2652,"kind":"person","name":"King-Jones Heidy","position":1,"cik":"0001794898","reported_name":"King-Jones Heidy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-04T01:34:14.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":27999,"price":14.5,"value":405985.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan."}],"balance_after":30844,"source":{"system":"sec-edgar","filing":"0001636282-26-000111","document":"wk-form4_1788485651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1794898/000163628226000111/wk-form4_1788485651.xml","form_type":"4"}},{"id":4037,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":337357,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4036,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":18232,"price":89.35,"value":1629029.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"The transaction reported reflects the sale of shares of the Issuer's common stock in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units (\"RSUs\"). This sale was made to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade made by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":79762,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4035,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":200,"price":89.04,"value":17808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4034,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":2016,"price":88.03,"value":177468.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.64 to $88.59, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":98194,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4033,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":4384,"price":87.11,"value":381890.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.60 to $87.57, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":100210,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4032,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":86.25,"value":77625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.60 to $86.53, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":104594,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4031,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:44.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":105494,"source":{"system":"sec-edgar","filing":"0001636282-26-000109","document":"wk-form4_1788485622.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000109/wk-form4_1788485622.xml","form_type":"4"}},{"id":4030,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:05.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":89.07,"value":35628.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":552540,"source":{"system":"sec-edgar","filing":"0001636282-26-000107","document":"wk-form4_1788485583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000107/wk-form4_1788485583.xml","form_type":"4"}},{"id":4029,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:05.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":3700,"price":88.06,"value":325822.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.68 to $88.67, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":552940,"source":{"system":"sec-edgar","filing":"0001636282-26-000107","document":"wk-form4_1788485583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000107/wk-form4_1788485583.xml","form_type":"4"}},{"id":4028,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:05.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":8400,"price":87.15,"value":732060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.67 to $87.65, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":556640,"source":{"system":"sec-edgar","filing":"0001636282-26-000107","document":"wk-form4_1788485583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000107/wk-form4_1788485583.xml","form_type":"4"}},{"id":4027,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:05.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":86.36,"value":215900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.67 to $86.66, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":565040,"source":{"system":"sec-edgar","filing":"0001636282-26-000107","document":"wk-form4_1788485583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000107/wk-form4_1788485583.xml","form_type":"4"}},{"id":691670,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date."}],"balance_after":45000,"derivative":{"exercise_price":10.39,"expiration_date":"2033-11-22","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":691669,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":104.68,"value":1046800.0,"ownership":{"direct":false,"nature":"By Sessions LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":9360,"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":691668,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":8000,"price":104.38,"value":835040.0,"ownership":{"direct":false,"nature":"By Sessions LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":19360,"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":691667,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":104.47,"value":522350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":691666,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T01:31:51.000Z","date":"2026-08-07","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":10.39,"value":51950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001636282-26-000102","document":"wk-form4_1786411908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000102/wk-form4_1786411908.xml","form_type":"4"}},{"id":695864,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":344857,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":695863,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":100,"price":97.1,"value":9710.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of\nSeptember 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":695862,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":2300,"price":96.3,"value":221490.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.85 to $96.82, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":98094,"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":695861,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":5100,"price":95.21,"value":485571.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.84 to $95.83, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":100394,"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":695860,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:32:04.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":105494,"source":{"system":"sec-edgar","filing":"0001636282-26-000100","document":"wk-form4_1785979922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000100/wk-form4_1785979922.xml","form_type":"4"}},{"id":695278,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":16,"price":97.46,"value":1559.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.46 to $97.47, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":567540,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":695277,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":1392,"price":96.82,"value":134773.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.45 to $97.43, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":567556,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":695276,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":5635,"price":95.93,"value":540565.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.45 to $96.44, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":568948,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":695275,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":7157,"price":95.1,"value":680630.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":574583,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":695274,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":800,"price":93.97,"value":75176.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":581740,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":718268,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-03T01:33:59.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":352357,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000088","document":"wk-form4_1783042436.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000088/wk-form4_1783042436.xml","form_type":"4"}},{"id":718267,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:59.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1725,"price":88.37,"value":152438.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.17 to $89.01, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-26-000088","document":"wk-form4_1783042436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000088/wk-form4_1783042436.xml","form_type":"4"}},{"id":718266,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:59.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":5775,"price":87.55,"value":505601.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.13 to $88.05, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":99719,"source":{"system":"sec-edgar","filing":"0001636282-26-000088","document":"wk-form4_1783042436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000088/wk-form4_1783042436.xml","form_type":"4"}},{"id":718265,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:59.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":105494,"source":{"system":"sec-edgar","filing":"0001636282-26-000088","document":"wk-form4_1783042436.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000088/wk-form4_1783042436.xml","form_type":"4"}},{"id":718648,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-03T01:33:02.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":8334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":305000,"derivative":{"exercise_price":27.46,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0001636282-26-000087","document":"wk-form4_1783042377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000087/wk-form4_1783042377.xml","form_type":"4"}},{"id":718647,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:02.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1834,"price":88.34,"value":162015.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001636282-26-000087","document":"wk-form4_1783042377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000087/wk-form4_1783042377.xml","form_type":"4"}},{"id":718646,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:02.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":6500,"price":87.52,"value":568880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":1834,"source":{"system":"sec-edgar","filing":"0001636282-26-000087","document":"wk-form4_1783042377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000087/wk-form4_1783042377.xml","form_type":"4"}},{"id":718645,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:33:02.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":8334,"price":27.46,"value":228851.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":8334,"source":{"system":"sec-edgar","filing":"0001636282-26-000087","document":"wk-form4_1783042377.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000087/wk-form4_1783042377.xml","form_type":"4"}},{"id":717168,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:32:04.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":590,"price":88.91,"value":52456.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.86 to $88.98, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":582540,"source":{"system":"sec-edgar","filing":"0001636282-26-000086","document":"wk-form4_1783042321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000086/wk-form4_1783042321.xml","form_type":"4"}},{"id":717167,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:32:04.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":4234,"price":88.12,"value":373100.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.82 to $88.75, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":583130,"source":{"system":"sec-edgar","filing":"0001636282-26-000086","document":"wk-form4_1783042321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000086/wk-form4_1783042321.xml","form_type":"4"}},{"id":717166,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:32:04.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":10176,"price":87.44,"value":889789.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.82 to $87.81, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":587364,"source":{"system":"sec-edgar","filing":"0001636282-26-000086","document":"wk-form4_1783042321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000086/wk-form4_1783042321.xml","form_type":"4"}},{"id":725608,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-27T01:31:44.000Z","date":"2026-06-25","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter\nof which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's\ncontinued employment with the Issuer."}],"balance_after":359857,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001853327-26-000008","document":"wk-form4_1782523902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000008/wk-form4_1782523902.xml","form_type":"4"}},{"id":725607,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-27T01:31:44.000Z","date":"2026-06-25","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":87.14,"value":871400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.78 to $87.43, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001853327-26-000008","document":"wk-form4_1782523902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000008/wk-form4_1782523902.xml","form_type":"4"}},{"id":725606,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-27T01:31:44.000Z","date":"2026-06-25","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":87.12,"value":435600.0,"ownership":{"direct":true},"balance_after":107994,"source":{"system":"sec-edgar","filing":"0001853327-26-000008","document":"wk-form4_1782523902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000008/wk-form4_1782523902.xml","form_type":"4"}},{"id":725605,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-27T01:31:44.000Z","date":"2026-06-25","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":14.5,"value":217500.0,"ownership":{"direct":true},"balance_after":112994,"source":{"system":"sec-edgar","filing":"0001853327-26-000008","document":"wk-form4_1782523902.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000008/wk-form4_1782523902.xml","form_type":"4"}},{"id":728581,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-06-24T01:56:26.000Z","date":"2026-06-23","kind":"exercise","planned":false,"acquired":false,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":666680},"source":{"system":"sec-edgar","filing":"0001104659-26-076967","document":"tm2618664-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000110465926076967/tm2618664-2_4seq1.xml","form_type":"4"}},{"id":728580,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T01:56:26.000Z","date":"2026-06-23","kind":"sale","planned":false,"acquired":false,"shares":4684781,"price":85.31,"value":399658667.11,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-076967","document":"tm2618664-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000110465926076967/tm2618664-2_4seq1.xml","form_type":"4"}},{"id":728579,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T01:56:26.000Z","date":"2026-06-23","kind":"exercise","planned":false,"acquired":true,"shares":666680,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":4684781,"source":{"system":"sec-edgar","filing":"0001104659-26-076967","document":"tm2618664-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000110465926076967/tm2618664-2_4seq1.xml","form_type":"4"}},{"id":728584,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T01:32:23.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":100,"value":2000000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."}],"balance_after":68606,"source":{"system":"sec-edgar","filing":"0001636282-26-000084","document":"wk-form4_1782264740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000084/wk-form4_1782264740.xml","form_type":"4"}},{"id":752329,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T01:32:02.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":313334,"derivative":{"exercise_price":27.46,"expiration_date":"2034-10-01","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001636282-26-000078","document":"wk-form4_1780536719.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000078/wk-form4_1780536719.xml","form_type":"4"}},{"id":752328,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:32:02.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":8333,"price":75,"value":624975.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001636282-26-000078","document":"wk-form4_1780536719.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000078/wk-form4_1780536719.xml","form_type":"4"}},{"id":752327,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":33045,"kind":"person","name":"Sloan Sheldon","position":1,"cik":"0002038798","reported_name":"Sloan Sheldon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:32:02.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":true,"shares":8333,"price":27.46,"value":228824.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."}],"balance_after":8333,"source":{"system":"sec-edgar","filing":"0001636282-26-000078","document":"wk-form4_1780536719.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2038798/000163628226000078/wk-form4_1780536719.xml","form_type":"4"}},{"id":750827,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:31:11.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":3294,"price":71.38,"value":235125.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.97 to $71.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":597540,"source":{"system":"sec-edgar","filing":"0001636282-26-000077","document":"wk-form4_1780536669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000077/wk-form4_1780536669.xml","form_type":"4"}},{"id":750826,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:31:11.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":8149,"price":70.5,"value":574504.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.96 to $70.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":600834,"source":{"system":"sec-edgar","filing":"0001636282-26-000077","document":"wk-form4_1780536669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000077/wk-form4_1780536669.xml","form_type":"4"}},{"id":750825,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:31:11.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":3557,"price":69.4,"value":246855.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.96 to $69.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":608983,"source":{"system":"sec-edgar","filing":"0001636282-26-000077","document":"wk-form4_1780536669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000077/wk-form4_1780536669.xml","form_type":"4"}},{"id":752003,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":374857,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":752002,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":3100,"price":72.06,"value":223386.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.54 to $72.14, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":752001,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":2599,"price":70.77,"value":183931.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.38 to $71.34, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":101094,"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":752000,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1801,"price":69.75,"value":125619.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":103693,"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":751999,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:30:41.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":14.5,"value":108750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."}],"balance_after":105494,"source":{"system":"sec-edgar","filing":"0001636282-26-000076","document":"wk-form4_1780536638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000163628226000076/wk-form4_1780536638.xml","form_type":"4"}},{"id":758408,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:58:06.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to Tomas Kiselak's continuous service to the Issuer through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001636282-26-000069","document":"wk-form4_1780091883.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000069/wk-form4_1780091883.xml","form_type":"4"}},{"id":758407,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":24935,"kind":"person","name":"Albers Jeffrey W.","position":1,"cik":"0001638474","reported_name":"Albers Jeffrey W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:56:32.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001636282-26-000068","document":"wk-form4_1780091789.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000068/wk-form4_1780091789.xml","form_type":"4"}},{"id":758406,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:55:47.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001636282-26-000067","document":"wk-form4_1780091744.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000067/wk-form4_1780091744.xml","form_type":"4"}},{"id":758405,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":36887,"kind":"person","name":"Stelzer Laurie","position":1,"cik":"0001644348","reported_name":"Stelzer Laurie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:55:24.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001636282-26-000066","document":"wk-form4_1780091721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000066/wk-form4_1780091721.xml","form_type":"4"}},{"id":758404,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:55:16.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001636282-26-000065","document":"wk-form4_1780091713.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000065/wk-form4_1780091713.xml","form_type":"4"}},{"id":758403,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":40792,"kind":"person","name":"Milligan Sandra","position":1,"cik":"0001859810","reported_name":"Milligan Sandra","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T21:54:49.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8026,"derivative":{"exercise_price":72.51,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":8026},"source":{"system":"sec-edgar","filing":"0001859810-26-000002","document":"wk-form4_1780091687.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000185981026000002/wk-form4_1780091687.xml","form_type":"4"}},{"id":786236,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-09T01:31:49.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":19269,"price":75.35,"value":1451919.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.15 to $75.71, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":88606,"source":{"system":"sec-edgar","filing":"0001636282-26-000053","document":"wk-form4_1778290306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000053/wk-form4_1778290306.xml","form_type":"4"}},{"id":786235,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-09T01:31:49.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":24814,"price":74.76,"value":1855094.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.15 to $75.14, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":107875,"source":{"system":"sec-edgar","filing":"0001636282-26-000053","document":"wk-form4_1778290306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000053/wk-form4_1778290306.xml","form_type":"4"}},{"id":786234,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-09T01:31:49.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":33513,"price":73.72,"value":2470578.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.15 to $74.14, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":132689,"source":{"system":"sec-edgar","filing":"0001636282-26-000053","document":"wk-form4_1778290306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000053/wk-form4_1778290306.xml","form_type":"4"}},{"id":786233,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-09T01:31:49.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":2404,"price":72.57,"value":174458.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 6, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.03 to $73.00, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."}],"balance_after":166202,"source":{"system":"sec-edgar","filing":"0001636282-26-000053","document":"wk-form4_1778290306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000053/wk-form4_1778290306.xml","form_type":"4"}},{"id":795809,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-02T01:35:12.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":382357,"derivative":{"exercise_price":14.5,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001853327-26-000005","document":"wk-form4_1777685708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000005/wk-form4_1777685708.xml","form_type":"4"}},{"id":795808,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2651,"kind":"person","name":"Burrows Scott L","position":1,"cik":"0001853327","reported_name":"Burrows Scott L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:35:12.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":71.37,"value":892125.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 67,476 restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":97994,"source":{"system":"sec-edgar","filing":"0001853327-26-000005","document":"wk-form4_1777685708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1853327/000185332726000005/wk-form4_1777685708.xml","form_type":"4"}}],"next_cursor":"2026-05-02T01:35:12.000000Z,795808"}